|Chemical name: Epoetin Alfa
Typical dosage: 10mg
Typical type: Capsule1
Revlimid® is a chemotherapy drug used for mantle cell lymphoma, multiple myeloma and myelodysplastic syndromes that cause severe anemia. It is currently only available as brand name and is available as an oral capsule.
Revlimid is a prescription chemotherapy medication that contains the active ingredient Lenalidomide. It is typically taken orally once daily for 21 days of a 28-day cycle, at which point the need for the drug is reassessed based on cancer progression or improvement.
Revlimid targets specific proteins within cancer cells and stops cancer from growing.
The major side effects of Revlimid include diarrhea, rash, nausea, constipation, tiredness, fever, itching, swelling of the limbs and skin and persistent cough.
Yes! 100% of Medicare Advantage plans and Medicare Part D plans cover Revlimid.1
Drug coverage may vary based on plan availability. You may be able to find Medicare Advantage plan options in your area that cover Revlimid.
Find Medicare Advantage plans with drug coverageCompare Plans
Or call TTY Users: 711 24/7 to speak with a licensed insurance agent.
Your copay and deductible costs for any prescription drug can vary depending on what coverage stage you’re in.
|Deductible stage||Typical copay stage|
|Your deductible is the amount of money you must spend on covered drugs before your Medicare drug coverage starts paying its share of costs.
In the deductible stage, you’re responsible for the full cost of your prescription drugs.
Some Medicare prescription drug plans have a $0 deductible. Medicare drug plans cannot have a deductible more than $415 in 2019.
|After you meet your Part D deductible, you enter the initial coverage period.
During this phase (the typical copay stage), you pay a copayment (flat fee) or coinsurance (percentage) for your covered medications.
|$5,795 – $23,178||$5,795 – $23,178|
Revlimid is used to treat mantle cell lymphoma after patients have relapsed or progressed after 2 prior therapies, one of which included bortezomib. Revlimid is used in combination with dexamethasone in the treatment of multiple myeloma.
Serious side effects of Revlimid include birth defects, increased risk of death in people with chronic lymphocytic leukemia (CLL), risks of new cancers, severe liver problems, severe skin reactions, tumor lysis syndrome, worsening of the present tumor, thyroid problems and risk of early death in patients with mantle cell lymphoma.
A severe decrease in white blood cells, or neutropenia, can occur with Revlimid and may require dose reductions. If neutropenia occurs, you may need an additional medication for adequate management.
Revlimid has also been associated with an increase in arterial and venous blood clots, pulmonary embolism, myocardial infarction and stroke when used with dexamethasone. If you develop symptoms of shortness of breath, chest pain or arm or leg swelling, get medical attention.
Prevention of blood clots with medication therapy is recommended.
You should not use Revlimid if you are pregnant due to the potential for severe birth defects or embryo-fetal death. Two negative pregnancy tests and two forms of contraception are required at least 4 weeks prior to, during and for 4 weeks after Revlimid treatment.
Patients using Revlimid who have kidney impairment may experience an increased rate of side effects.
This article is for informational purposes only. It is not healthcare advice, treatment, or diagnosis. It is not an endorsement of or recommendation for this medication. Speak to your doctor or healthcare provider about your specific healthcare needs, including your prescription medications. Only take medication as directed by your doctor.
Coverage and costs of prescription medications will vary by Medicare plan. Not all plans are available in all areas.
Written by Hayden Gharibyar, Pharm.D.